Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

LB54640

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

Rhythm · Phase 2 · Completed · Enrollment 28

NCT06046443

ArmPopulationDoseWeeksEstimandWeight change
Bivamelagon Low dose (200 milligrams [mg])Obesity or overweightn/r14n/rn/r
Bivamelagon Middle dose (400 mg)Obesity or overweight400 mg14n/rn/r
Bivamelagon High dose (600 mg)Obesity or overweight600 mg14n/rn/r
PlaceboObesity or overweightn/r14n/rn/r
Open-label BivamelagonObesity or overweightn/r14n/rn/r